The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Kohei KakuChristoph WannerStefan D AnkerStuart PocockAtsutaka YasuiMichaela MattheusSøren S LundPublished in: Diabetes, obesity & metabolism (2022)
Empagliflozin reduced the total burden of cardiovascular and hospitalization events in Asian and non-Asian EMPA-REG OUTCOME participants with T2D and established ASCVD, consistent with the overall trial population.